Skip to main content
Fig. 3 | BMC Microbiology

Fig. 3

From: Azithromycin and the microbiota of cystic fibrosis sputum

Fig. 3

Impact of azithromycin on the CF microbiome. a Alpha diversity (within patients) of Pre (i.e. Pre and Day 0) and Post azithromycin samples based on Shannon diversity index (SDI) metrics for the whole cohort (n = 38 patients) and the naïve cohort (n = 29). Wilcoxon rank sum test was performed. b Alpha diversity of baseline and Post azithromycin samples based on SDI metrics for the whole cohort and the naïve cohort. Wilcoxon signed-rank test was performed. Boxplots show the median with IQR and the ends of the whiskers mark the 10th and the 90th percentiles. c ASVs that were identified to be significantly different (p adjusted < 0.05) in relative abundance between Pre (i.e. Pre and Day 0) and Post groups, as detected by DESeq2

Back to article page